Table 1.
Details of leading COVID-19 vaccines with known efficacy (as of June 2, 2021).
| Name | Developer | Country | Type | Efficacy (Dose) | Status | Storage |
| Convidecia (or Ad5-nCoV) | CanSino | China | Adenovirus | 65.28% (single dose) | Approved in China, emergency use in Chile, Hungary, Pakistan, etc | Stable in regular refrigerator for at least 6 months |
| BBIBP-CorV | Sinopharm | China | Inactivated | 86% (2 doses, 3 weeks apart) | Approved in UAEa and Bahrain; emergency use in Egypt and Jordan | Stable in regular refrigerator for at least 6 months |
| —b | Sinopharm-Wuhan | China | Inactivated | 72.8% | Limited use in China and UAE | Stable in regular refrigerator for at least 6 months |
| CoronaVac (formerly PiCoVacc) | Sinovac | China | Inactivated | 50.38%-78% (2 doses, 2 weeks apart) | Limited use in China, Brazil, etc | Stable in regular refrigerator for at least 6 months |
| Covaxin (or BBV152 A, B, C) | Bharat Biotech | India | Inactivated | 78% (2 doses, 4 weeks apart) | Emergency use in India, Philippines, Zimbabwe, etc | At least a week at room temperature |
| Sputnik V | Gamaleya | Russia | Adenovirus | 91.4% (2 doses, 3 weeks apart) | Early use in Russia | Freezer storage |
| EpiVacCorona | Vector Institute | Russia | Protein | — (2 doses, 3 weeks apart) | Limited use in Russia and Turkmenistan | Stable in refrigerator for up to 2 years |
| Vaxzevria (or AZD1222/Covishield) | Oxford-AstraZeneca | UKc and Sweden | Adenovirus | 60%-90% (2 doses, 4 weeks apart) | Stopped use in Denmark and Norway; emergency use in UK, Lebanon, Canada, etc | Stable in regular refrigerator for at least 6 months |
| Ad26.COV2.S | Johnson & Johnson | USd | Adenovirus | 57%-72% (1 dose) | Stopped use in Denmark and Finland; emergency use in US, the European Union, etc | Up to 2 years at –4°F (–20°C) or up to 3 months at 36-46°F (2-8°C) |
| mRNA-1273 | Moderna | US | mRNA | 94.5% (2 doses, 4 weeks apart) | Approved in Canada; emergency use in US, UK, etc | Stable in refrigerator for up to 30 days |
| NVX-CoV2373 | Novavax | US | Protein | 49.4%-89.3% (2 doses, 3 weeks apart) | — | Stable in regular refrigerator for at least 6 months |
| Tozinameran or Comirnaty or BNT162b2 | Pfizer-BioNTech | US and Germany | mRNA | 95% (2 doses, 3 weeks apart) | Approved in Canada, Saudi Arabia, UAE, Bahrain, and Kuwait; emergency use in UK, US, etc | Freezer storage only at –94°F (–70°C) |
aUAE: United Arab Emirates.
bNot available.
cUS: United States.
dUK: United Kingdom.